![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » U.S. to Buy 500,000 Extra Doses of AstraZeneca’s COVID-19 Therapy
U.S. to Buy 500,000 Extra Doses of AstraZeneca’s COVID-19 Therapy
January 14, 2022
The Biden administration will purchase a further 500,000 doses of AstraZeneca’s long-acting COVID-19 antibody therapy Evusheld, bringing the government’s total order to more than 1 million doses.
The tixagevimab/cilgavimab combination, which secured FDA Emergency Use Authorization in December, is indicated for immunocompromised people 12 years and up who may be unable to mount a proper immune response to a COVID-19 vaccine as well as those who can’t be given a COVID-19 vaccine.
AstraZeneca is confident that the antibody can offer protection against the Omicron variant. In two laboratory studies, the therapy was shown to maintain neutralizing power against the Omicron strain.
Upcoming Events
-
21Oct